No translate

Phạm Thanh Phong; Huỳnh Lê Trọng Tường; Trần Diệu Hiền

doi:10.58354/jvc.93.2021.1261

Home

NGHIÊN CỨU LÂM SÀNG Issue: Số 93, 2021 BỆNH SUY TIM

No translate

Published: September 7, 2026

10.58354/jvc.93.2021.1261

Abstract

No translate

Keywords

No translate

References

1. Oren, R.M., Hyponatremia in congestive heart failure. Am J Cardiol, 2005. 95(9a): p. 2b-7b.

DOI: doi.org/10.1016/j.amjcard.2005.03.002

2. Omar, H.R., R. Charnigo, and M. Guglin, Prognostic Significance of Discharge Hyponatremia in Heart Failure Patients With Normal Admission Sodium (from the ESCAPE Trial). Am J Cardiol, 2017. 120(4): p. 607-615.

DOI: doi.org/10.1016/j.amjcard.2017.05.030

3. Vishram-Nielsen, J.K. and F. Gustafsson, Vasopressin and Vasopressin Antagonists in Heart Failure. Handb Exp Pharmacol, 2017. 243: p. 307-328.

DOI: doi.org/10.1007/164_2017_28

4. Kinugawa, K., et al., Efficacy and safety of Tolvaptan in heart failure patients with volume overload. Circ J, 2014. 78(4): p. 844-52.

DOI: doi.org/10.1253/circj.cj-14-0126

5. Watanabe, K., et al., Short-term effects of low-dose Tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol, 2012. 60(6): p. 462-9.

DOI: doi.org/10.1016/j.jjcc.2012.09.002

6. ESC, Corrigendumto:‘2016ESCGuidelinesforthediagnosisand treatment of acute and chronic heart failure. Eur Heart J, 2017.

7. Gheorghiade, M., et al., Characterization and prognostic value of persistent hyponatremia in patients with severeheartfailureintheESCAPETrial.Arch Intern Med, 2007. 167(18): p. 1998-2005.

DOI: doi.org/10.1001/archinte.167.18.1998

8. Schrier, R.W., et al., Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.2006. 355(20): p. 2099-2112.

DOI: doi.org/10.1056/nejmoa065181

9. Patra, S., et al., Short term efficacy and safety of low dose tolvaptan in patients with acute decompensated heart failure with hyponatremia: a prospective observational pilot study from a single center in South India. 2014. 15(1): p. 1.

DOI: doi.org/10.4103/1995-705x.132136

10.

10. Cavalcante, J.L., S. Khan, and M. Gheorghiade, EVERESTstudy:EfficacyofVasopressinAntagonisminHeartFailureOutcomeStudywithTolvaptan.Expert Rev Cardiovasc Ther, 2008. 6(10): p. 1331-8.

DOI: doi.org/10.1586/14779072.6.10.1331

11.

11. Payvar, S., et al., Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. Eur J Heart Fail, 2013. 15(12): p. 1382-9.

DOI: doi.org/10.1093/eurjhf/hft113

Tác giả

Phạm Thanh Phong: Bệnh viện Đa khoa Trung ương Cần Thơ; Huỳnh Lê Trọng Tường: Bệnh viện Đa khoa Trung ương Cần Thơ; Trần Diệu Hiền: Bệnh viện Đa khoa Trung ương Cần Thơ;